Caribou Biosciences shuts down after failing to fund Phase 3 lymphoma trialRestructuringCaribou Biosciences·Biotech·6 Oct·Statnews
Iambic Therapeutics raises $150 million in IPODeal · IPOIambic Therapeutics·Biotech·14 Oct·BioPharma Dive
BioNTech says its mRNA head and neck cancer therapy missed a trial objectiveBioNTech·Biotech·13 Oct·BioPharma Dive